Salesforce (CRM) is back in focus after Viz.ai introduced a real-time clinical intelligence service for Agentforce Life Sciences, integrating Salesforce’s agentic platform directly with data from nearly 2,000 US hospitals.

Even with the Viz.ai tie up highlighting Salesforce’s push into healthcare and life sciences agents, momentum has cooled, with a 30 day share price return of a 13.42% decline and a 1 year total shareholder return of a 31.4% decline. However, the 3 year total shareholder return of 39.84% and 5 year total shareholder return of 1.93% show a mixed longer term picture.

If you are watching how AI reshapes enterprise software, it can be useful to scan other high growth tech and AI names through high growth tech and AI stocks for fresh ideas beyond Salesforce.

With Salesforce shares down sharply over 12 months yet trading at an estimated 40.7% intrinsic discount and about 44.5% below the average analyst target, you have to ask: is pessimism overdone, or is the market correctly pricing in future growth?

Most Popular Narrative: 15.1% Undervalued

According to the most followed narrative for Salesforce, a fair value of $268.76 sits well above the recent $228.09 close, which is driving the view that current pricing leaves a meaningful gap to that estimate.

Salesforce is redefining what CRM means in an AI-native enterprise. The real power of agentic AI lies in controlling workflows, not just analyzing data. By embedding intelligence directly into revenue and service operations, Salesforce aims to become indispensable infrastructure rather than optional software.

Curious what kind of revenue growth, profitability mix, and future profit multiple need to line up to justify that fair value gap? The narrative leans on disciplined earnings expansion, strong cash generation, and a premium attached to Salesforce acting as the workflow "brain" across industries. The exact mix of assumptions is where the story gets interesting.

Result: Fair Value of $268.76 (UNDERVALUED)

However, you still need to watch for two pressure points: customers pushing back on higher AI pricing, and bigger platforms crowding into the same workflow territory.

Build Your Own Salesforce Narrative

If you look at the numbers and come away with a different story, or simply prefer to test your own assumptions, you can build a complete Salesforce view in just a few minutes with Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Salesforce.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at Salesforce. Use focused stock lists to spot opportunities you might otherwise miss.

• Target potential value upside by scanning these 880 undervalued stocks based on cash flows that may be pricing in more caution than their cash flows suggest.
• Ride the AI momentum thoughtfully by reviewing these 24 AI penny stocks that are directly exposed to practical, real world adoption of artificial intelligence.
• Strengthen your income stream by checking these 12 dividend stocks with yields > 3% that might offer more reliable cash returns than growth stories alone.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.